|
시장보고서
상품코드
1549989
세계의 경도 인지장애 시장 : 질환 유형, 연령, 적응증, 치료법, 지역별 예측(-2032년)Global Mild Cognitive Impairment Market Research Report By Disease Type, By Age, By Indication, By Treatment, And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032 |
||||||
경도 인지장애 시장 규모는 2023년 19억 4,000만 달러, 22024년 20억 5,000만 달러에서 예측 기간 중 5.95CAGR로 추이하며, 2032년에는 32억 5,000만 달러 규모로 성장할 것으로 예측됩니다.
경도 인지장애 시장의 주요 촉진요인은 세계에서 경도 인지장애의 유병률 증가와 경도 인지장애에 대한 인식이 높아지는 것입니다. 다약제 병용 및 동반 질환의 조절로 인해 치료 옵션이 복잡해져 세계 시장 성장이 둔화될 것으로 예상되지만, 경도 인지장애의 조기 진단에 대한 기술 개발은 수익성 높은 시장 전망을 가져올 것으로 예상됩니다.
지역별 인사이트
북미 시장은 2022년 42.60%로 가장 큰 시장 점유율을 차지할 것으로 예상되며, 예측 기간 중 4.97%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 약 13억 1,000만 달러 규모에 달할 것으로 예상됩니다. 아시아태평양은 예측 기간 중 6.91%의 가장 빠른 CAGR로 성장할 것으로 예상됩니다. 북미의 경도인지장애 시장은 향후 견고한 성장세를 보일 것으로 예상됩니다. 의료 인프라에 대한 투자와 최신 의료 솔루션에 대한 인식이 높아지면서 시장 성장을 더욱 촉진할 것으로 예상됩니다. 기존 기업과 신규 진출기업은 더 나은 수술 결과에 대한 수요 증가에 대응하기 위해 개선된 기술을 활용하여 이러한 잠재력을 포착할 준비를 하고 있습니다.
유럽 시장은 기술 발전, 의료비 상승, 경도 인지장애에 대한 부담 증가로 인해 시장 점유율 2위를 차지하고 있습니다. 독일이 가장 큰 시장 점유율을 차지하고 있으며, 영국은 유럽에서 가장 빠른 성장을 보일 것으로 예상됩니다.
세계의 경도 인지장애 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추이·예측, 각종 구분·지역별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 개요
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
- 촉진요인
- 세계에서 경도 인지장애 부담의 증가
- 경도 인지장애에 관한 의식의 향상
- 억제요인
- 다제병용과 병존 질환 관리에 의한 치료 전략의 복잡화
- 기회
- 경도 인지장애의 조기진단을 향한 기술의 진보
제5장 시장 요인 분석
- Porter's Five Forces 분석
- COVID-19의 영향
제6장 세계의 경도 인지장애 시장 : 질환 유형별
- 개요
- 건망성 경도 인지장애
- 비건망성 경도 인지장애
제7장 세계의 경도 인지장애 시장 : 연령별
- 개요
- 소아
- 성인
- 고령자
제8장 세계의 경도 인지장애 시장 : 적응증별
- 개요
- LEWY BODY DEMENTIA
- 파킨슨병 인지증
- 알츠하이머병
- 혈관성 인지증
- 기타
제9장 세계의 경도 인지장애 시장 : 치료별
- 개요
- 약제
- 콜린에스테라아제 저해제
- 벤조디아제핀
- 글루타민산 저해제
- 항히스타민약
- MAO 저해제
- 프로톤펌프 저해제
- 기타
- 치료
- 인지 자극치료
- 인지 행동 요법(CBT)
제10장 세계의 경도 인지장애 시장 : 지역별
- 개요
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제11장 경쟁 구도
- 시장 점유율 분석
- 경쟁 대시보드
- 공개 기업의 주식 개요
- 비교 분석 : 주요 기업의 재무 동향
- 주요 개발·성장 전략
제12장 기업 개요
- JOHNSON & JOHNSON SERVICES, INC
- PFIZER INC
- NOVARTIS AG
- ABBVIE INC.
- BIOGEN
- EISAI CO., LTD.
- AUROBINDO PHARMA
- SUN PHARMACEUTICAL INDUSTRIES LTD.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- TAJ PHARMACEUTICALS LTD.
제13장 데이터 인용
KSA 24.09.20Global Mild Cognitive Impairment Market Research Report By Disease Type (Amnestic MCI and Non-Amnestic MCI), By Age (Child, Adult, Geriatric), By Indication (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, and Others) By Treatment (Medication (Cholinesterase Inhibitors, Benzodiazepines, Glutamate Inhibitors, Antihistamines, Mao Inhibitors, Proton Pump Inhibitors, and Others), Therapy (Cognitive Stimulation Therapy, Cognitive Behavioural Therapy (CBT)), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World - Forecast Till 2032
Market Overview
The market size for mild cognitive impairment was estimated to be USD 1.94 billion in 2023. The global mild cognitive impairment industry is expected to expand from USD 2.05 billion in 2024 to USD 3.25 billion by 2032, with a compound annual growth rate (CAGR) of 5.95% during the forecast period (2024-2032).
The growing prevalence of mild cognitive impairment around the world, as well as increased awareness of mild cognitive impairment, are the primary drivers of the Mild Cognitive Impairment Market. However, polypharmacy and controlling comorbidities complicate treatment options, which is projected to slow worldwide market growth. Nonetheless, technological developments in the early diagnosis of MCI around the world are expected to provide profitable market prospects. The rising global prevalence of moderate cognitive impairment (MCI) is a primary driver of the global MCI treatment industry.
Marketing Segmentation
Mild Cognitive Impairment Market Segmentation by Disease Type, Amnestic MCI, and Non-Amnestic MCI.
The mild cognitive impairment market segmentation by age comprises child, adult, and geriatric.
The Mild Cognitive Impairment Market has been classified according to indication: Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and others.
The Mild Cognitive Impairment Market has been divided into two segments: medicine and therapy.
Regional insights
The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American mild cognitive impairment market had the greatest market share of 42.60% in 2022 and is expected to reach roughly USD 01.31 billion by 2032, growing at a 4.97% CAGR over the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 6.91% over the forecast period. The North American mild cognitive impairment market is expected to increase steadily in the future. Investments in healthcare infrastructure and increased awareness of modern medical solutions are projected to propel market growth even further. Both established firms and new entrants are ready to seize these possibilities, utilizing technological improvements to address the growing need for better surgical outcomes.
Europe's mild cognitive impairment market accounted for the second-largest market share due to technological improvements, rising healthcare costs, and an increased burden of mild cognitive impairment. Furthermore, the German mild cognitive impairment market is expected to have the biggest market share, with the UK mild cognitive impairment market forecast to be the fastest expanding market in Europe.
The Asia-Pacific mild cognitive impairment market is predicted to develop the fastest from 2024 to 2032, owing to a large patient population, an increasing number of mild cognitive cases, and favorable regulatory regulations. Furthermore, prominent companies in the mild cognitive impairment market are aggressively expanding into this region, propelling the regional market forward. Furthermore, China's mild cognitive impairment market had the greatest market share, while India's mild cognitive impairment market is expected to be the fastest expanding in the Asia-Pacific region.
Major Players
Key players in the mild cognitive impairment market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), AbbVie Inc. (US), Biogen (Switzerland), Eisai Co., Ltd. (Japan), Aurobindo Pharma (India), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), and Taj Pharmaceuticals Limited (India).
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
- 3.1 OVERVIEW
- 3.2 DATA FLOW
- 3.2.1 Data Mining Process
- 3.3 PURCHASED DATABASE:
- 3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research data flow:
- 3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research DATA FLOW:
- 3.5.2 Primary Research: Number of Interviews conducted
- 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
- 3.7 DATA FORECASTING
- 3.7.1 Data forecasting Technique
- 3.8 DATA MODELLING
- 3.8.1 Microeconomic Factor Analysis:
- 3.8.2 Data MODELLING:
- 3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
- 4.1 INTRODUCTION
- 4.2 DRIVERS
- 4.2.1 Increasing burden of Mild cognitive impairment across the globe
- 4.2.2 Rising awareness associated with mild cognitive impairment
- 4.3 RESTRAINTS
- 4.3.1 Polypharmacy and managing comorbidities complicate treatment strategies
- 4.4 OPPORTUNITY
- 4.4.1 Technological advancements for early diagnosis of MCI
5 MARKET FACTOR ANALYSIS
- 5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 Threat of New Entrants
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 Threat of Substitutes
- 5.1.4 Bargaining Power of Buyers
- 5.1.5 Intensity of Rivalry
- 5.2 IMPACT OF COVID-19 ON THE GLOBAL MILD COGNITIVE IMPAIRMENT MARKET
6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE
- 6.1 OVERVIEW
- 6.2 AMNESTIC MCI
- 6.3 NON-AMNESTIC MCI
7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE
- 7.1 OVERVIEW
- 7.2 CHILD
- 7.3 ADULT
- 7.4 GERIATRIC
8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION
- 8.1 OVERVIEW
- 8.2 LEWY BODY DEMENTIA
- 8.3 PARKINSON'S DISEASE DEMENTIA
- 8.4 ALZHEIMER'S DISEASE
- 8.5 VASCULAR DEMENTIA
- 8.6 OTHERS
9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT
- 9.1 OVERVIEW
- 9.2 MEDICATION
- 9.2.1 Cholinesterase Inhibitors
- 9.2.2 Benzodiazepines
- 9.2.3 Glutamate Inhibitors
- 9.2.4 Antihistamines
- 9.2.5 Mao Inhibitors
- 9.2.6 Proton Pump Inhibitors
- 9.2.7 Others
- 9.3 THERAPY
- 9.3.1 Cognitive Stimulation Therapy
- 9.3.2 Cognitive Behavioural Therapy (CBT)
10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION
- 10.1 OVERVIEW
- 10.2 NORTH AMERICA
- 10.2.1 us
- 10.2.2 canada
- 10.3 EUROPE
- 10.3.1 Germany
- 10.3.2 France
- 10.3.3 UK
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Rest of Europe
- 10.4 ASIA-PACIFIC
- 10.4.1 China
- 10.4.2 India
- 10.4.3 Japan
- 10.4.4 South Korea
- 10.4.5 AUSTRALIA
- 10.4.6 Rest of Asia-Pacific
- 10.5 REST OF THE WORLD
- 10.5.1 Middle East & Africa
- 10.5.2 Latin America
11 COMPETITIVE LANDSCAPE
- 11.1 INTRODUCTION
- 11.2 MARKET SHARE ANALYSIS,
- 11.3 COMPETITOR DASHBOARD
- 11.4 PUBLIC PLAYERS STOCK SUMMARY
- 11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
- 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 product launch / Product approval
12 COMPANY PROFILES
- 12.1 JOHNSON & JOHNSON SERVICES, INC
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 productS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
- 12.2 PFIZER INC
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 productS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
- 12.3 NOVARTIS AG
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 productS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
- 12.4 ABBVIE INC.
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
- 12.5 BIOGEN
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
- 12.6 EISAI CO., LTD.
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 KEY STRATEGIES
- 12.7 AUROBINDO PHARMA
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 KEY STRATEGIES
- 12.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
- 12.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
- 12.10 TAJ PHARMACEUTICALS LTD.
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES
